| Old Articles: <Older 22511-22520 Newer> |
|---|
 |
The Motley Fool
April 24, 2007
Ryan Fuhrmann |
Boston Scientific Regains Consciousness Recent Boston Scientific results show glimmers of hope. At current prices, the risk/reward tradeoff appears favorable enough to warrant a full checkup on the stock.   |
The Motley Fool
April 24, 2007
Ryan Fuhrmann |
Earnings-eluting Time at Boston Scientific: Fool by Numbers The medical device firm released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 24, 2007
Brian Lawler |
Is the Worst Over for QLT? The biopharma announces another dismal quarter of declining sales for its top compound. |
The Motley Fool
April 24, 2007
Rick Aristotle Munarriz |
Honey, I Shrunk the Military Robots The consumer robotics specialist gets small with its latest creation. iRobot machines can get soldiers out of combative jams and consumers out of filthy homes, so it may be just a matter of time before shareholders catch a break, too. |
The Motley Fool
April 24, 2007 |
Diedrich Coffee Stirs Sales: Fool by Numbers The gourmet coffee maker released third-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 24, 2007
Brian Lawler |
Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes. |
The Motley Fool
April 24, 2007
Tom Taulli |
Wipro Hungry for Deals The Indian IT outsourcer may seek acquisitions to keep growing. Investors, take note. |
The Motley Fool
April 24, 2007
Brian Lawler |
AtheroGenics Loses a Partner The specialty drug maker's drug-development partner bails. Waiting around for years on more clinical trial results for a drug with such unproven efficacy is not something that is a recipe for success with specialty pharma stock investing. |
The Motley Fool
April 24, 2007
Rick Aristotle Munarriz |
Teaming Up on the Google Goliath Yahoo! and eBay join forces to take on Google's e-payment service. Investors, take note. |
The Motley Fool
April 24, 2007
Brian Lawler |
MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal. |
| <Older 22511-22520 Newer> Return to current articles. |
